Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1293

1.

Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.

Mandelblatt JS, Lawrence WF, Gaffikin L, Limpahayom KK, Lumbiganon P, Warakamin S, King J, Yi B, Ringers P, Blumenthal PD.

J Natl Cancer Inst. 2002 Oct 2;94(19):1469-83.

PMID:
12359856
2.
3.

Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.

Praditsitthikorn N, Teerawattananon Y, Tantivess S, Limwattananon S, Riewpaiboon A, Chichareon S, Ieumwananonthachai N, Tangcharoensathien V.

Pharmacoeconomics. 2011 Sep;29(9):781-806. doi: 10.2165/11586560-000000000-00000.

PMID:
21838332
4.

Benefits and costs of using HPV testing to screen for cervical cancer.

Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, Gold K, Barter J, Shah K.

JAMA. 2002 May 8;287(18):2372-81.

PMID:
11988058
5.

Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.

Vijayaraghavan A, Efrusy M, Lindeque G, Dreyer G, Santas C.

Gynecol Oncol. 2009 Feb;112(2):377-83. doi: 10.1016/j.ygyno.2008.08.030. Epub 2008 Dec 11.

PMID:
19081611
6.

Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.

Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E.

J Natl Cancer Inst. 2004 Apr 21;96(8):604-15.

PMID:
15100338
7.

Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus.

Goldie SJ, Freedberg KA, Weinstein MC, Wright TC, Kuntz KM.

Am J Med. 2001 Aug;111(2):140-9.

PMID:
11498068
8.

Cost-effectiveness of cervical-cancer screening in five developing countries.

Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C, Wright TC; Alliance for Cervical Cancer Prevention Cost Working Group.

N Engl J Med. 2005 Nov 17;353(20):2158-68.

9.

Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS).

Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, Solomon D, Goldie SJ; ALTS Group.

J Natl Cancer Inst. 2006 Jan 18;98(2):92-100.

PMID:
16418511
10.

[Effectiveness and health economic analysis of strategies on cervical cancer screening and early diagnosis and treatment].

Zhao FH, Chen JF, Gao XH, Gao LM, Liu QG, Liu ZH, Xu H, Ma JF, Ma L, Xu XL, Hu SY, Ning Y, Shi JF, Qiao YL.

Zhonghua Zhong Liu Za Zhi. 2012 Aug;34(8):632-6. doi: 10.3760/cma.j.issn.0253-3766.2012.08.017. Chinese.

PMID:
23159002
11.
12.

Design and methods of the evaluation of an HPV-based cervical cancer screening strategy in Mexico: The Morelos HPV Study.

Flores Y, Shah K, Lazcano E, Hernández M, Bishai D, Ferris DG, Lörincz A, Hernández P, Salmerón J; Morelos HPV Study Collaborators.

Salud Publica Mex. 2002 Jul-Aug;44(4):335-44.

PMID:
12216521
13.

Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries.

Maxwell GL, Carlson JW, Ochoa M, Krivak T, Rose GS, Myers ER.

Obstet Gynecol. 2002 Oct;100(4):740-8.

PMID:
12383543
14.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444. Epub 2009 Jan 13.

PMID:
19141778
15.

The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.

Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA.

Ann Intern Med. 1999 Jan 19;130(2):97-107.

PMID:
10068381
16.

Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M.

J Natl Cancer Inst. 2003 Jan 1;95(1):46-52.

PMID:
12509400
17.

Oncogenic human papillomavirus (HPV) infection and uterine cervical cancer: a screening strategy in the perspective of rural India.

Duttagupta C, Sengupta S, Roy M, Sengupta D, Chakraborty S, Bhattacharya P, Roy S, Ghosh S.

Eur J Cancer Prev. 2002 Oct;11(5):447-56.

PMID:
12394242
18.

Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness.

Melnikow J, Kulasingam S, Slee C, Helms LJ, Kuppermann M, Birch S, McGahan CE, Coldman A, Chan BK, Sawaya GF.

Obstet Gynecol. 2010 Nov;116(5):1158-70. doi: 10.1097/AOG.0b013e3181f88e72.

PMID:
20966702
19.

Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.

Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E.

Arch Med Res. 2009 Aug;40(6):503-13. doi: 10.1016/j.arcmed.2009.08.004.

PMID:
19853192
20.

Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.

Lonky NM, Hunter MI, Sadeghi M, Edwards G, Bajamundi K, Monk BJ.

J Low Genit Tract Dis. 2007 Oct;11(4):258-64.

PMID:
17917570

Supplemental Content

Support Center